HAIER BIOMEDICAL(688139) 新浪财经·2025-04-01 10:35Core Viewpoint - The company reported its 2024 annual results, showing a slight revenue increase but a decline in net profit, with expectations for significant growth in overseas markets in 2025 [1][2]. Financial Performance - In 2024, the company achieved revenue of 2.28 billion yuan (+0.1%) and a net profit attributable to shareholders of 367 million yuan (-9.7%), with a non-recurring net profit of 321 million yuan (-2.9%) [1]. - Quarterly revenue for 2024 was 690 million yuan in Q1, 540 million yuan in Q2, 560 million yuan in Q3, and 500 million yuan in Q4, showing a quarterly growth of +0%, -8.1%, +0.5%, and +10.4% respectively [1]. - Quarterly net profit attributable to shareholders was 140 million yuan in Q1, 97 million yuan in Q2, 75 million yuan in Q3, and 57 million yuan in Q4, with changes of +0.1%, -31.4%, -5%, and +17.6% respectively [1]. Business Segments - The storage segment experienced negative growth, but excluding the solar vaccine cold storage, it remained flat; non-storage revenue grew by 21% [1]. - The low-temperature storage business faced challenges but showed improvement, with the decline primarily due to delays in solar vaccine orders. The second half of the year saw a narrowing decline, achieving positive growth in Q4 [2]. - Non-low-temperature storage equipment, including automated medication, laboratory consumables, and digital public health, continued to grow rapidly [2]. Market Expansion - The company is deepening its global presence, with overseas markets (excluding solar vaccine solutions) achieving double-digit growth. The company has established localized teams in key countries such as the USA, UK, Netherlands, Singapore, and India [2]. - The company has received local certification for 56 new product models, totaling over 400 overseas product certifications, and is accelerating local construction to shorten product delivery cycles [2]. Profit Forecast - The company forecasts net profit attributable to shareholders of 440 million yuan in 2025, 520 million yuan in 2026, and 600 million yuan in 2027, indicating steady growth and potential for future acquisitions [3].